Media Resources
Living Cell Technologies is committed to providing up-to-the-minute information about our research, scientific results, clinical trials and productisation. Here you will find the latest media resources including an archive of previous material over the period of the company’s operation.
Endogenous Insulin Delivery on Demand
12 November, 2009 - - A paper submitted to the Autumn 2009 issue of International Clinical Trials (ICT) magazine by Paul L J Tan, Kathleen Durbin and Robert Elliott.
The full Autumn 2009 issue of ICT can be found at: www.samedanltd.com.
Click here to download this release in PDF format.LCT Presents at AusBiotech 2009
28 October, 2009 - -
LCT's Paul Tan was invited to be one of the key speakers at the AusBiotech 2009 conference and presented LCT's experience in "Meeting international guidelines for first-in-human cell therapy".
Click here to download this release in PDF format.Xenotransplantation briefing part 1
21 August, 2009 - Xenotransplantation
Click here to download this release.
Xenotransplantation briefing part 2
21 August, 2009 - Xenotransplantation
LCT's New Zealand Trial Profiled on TV One
17 July, 2009 - LCT New Zealand
Click here to download this release in PDF format.New Pig Breeding Facility Opened
17 July, 2009 - LCT New Zealand
Click here to download this release in PDF format.
Living Cell Technologies Reports Insulin Independence in Two Patients Following Recent Implants of DIABECELL® in Diabetes Clinical Trial
05 May, 2009 - - Living Cell Technologies Reports Insulin Independence in Two Patients Following Recent Implants of DIABECELL® in Diabetes Clinical Trial 5 May 2009 - Sydney, Australia, Auckland, New Zealand- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today reported that following the latest implants of DIABECELL®, two recipients with long standing insulin dependent diabetes currently do not require insulin injections.
DIABECELL® is LCT's encapsulated insulin-producing porcine pancreatic islet cells.
To date, seven patients with insulin dependent diabetes have received between one and three implants of DIABECELL® without remarkable adverse events in LCT's on-going Phase I/IIa clinical trial.
LCT Medical Director, Professor Bob Elliott, who is in San Diego, USA, delivering a plenary lecture on DIABECELL® at the Annual Meeting of the International Society for Cell Therapy, said, "Having two patients going off their insulin injections gives me tremendous confidence that we have a treatment which can return people with diabetes to a normal life.
All patients followed-up show improvement of diabetes control with better glycated haemoglobin (%HbA1c) levels. I am extremely pleased to see all blood glucose levels in their seven-point recordings to be in the normal range, even with a lower daily dose of insulin."
LCT CEO, Dr Paul Tan added, "The dose escalation and the tightening of the quality specifications of DIABECELL® for the last two implants have led to a very satisfying outcome with the recipients becoming insulin independent and we look forward to an equally positive outcome for future patients. LCT expects DIABECELL® to be established as a product of exceptional commercial value".
Progress Report of DIABECELL® Phase I/IIa Clinical Trial
•· The trial is an open labelled Phase I/IIa investigation to obtain data on the safety and preliminary efficacy of DIABECELL®, encapsulated neonatal porcine pancreatic islets, without the use of immunosuppressive drugs.
•· The trial started in Moscow in 2007 and is intended to enrol a total of 10 patients with type 1 diabetes who have given informed consent for their participation. The trial is being monitored by Geny Research Group Inc, a U.S.-based contract research organization.
•· To date, seven insulin dependent diabetes patients have been implanted:
•· The trial was designed for Patients #1 - #5 to receive two implants of DIABECELL® at the dose of 5,000 Islet Equivalents per kg body weight (IEQ/kg) at least 6 months apart and for Patients #6 - #10 to receive one implant of 10,000 IEQ/kg.
•· Based on clinical assessment, amendments to the protocol were requested by the investigators to optimise the treatment in this dose-finding study. Patients #3, #4 and #5 received implants of 5,000 and 10,000 IEQ/kg. Patient #2 received a third implant of 10,000 IEQ/kg.
•· As summarised in the following Table, patients have been followed up from a minimum of 18 weeks to 96 weeks. Patient #6 failed to attend follow up after 20 weeks and attempts to resume follow-up continue.
•· There were no remarkable adverse events following implants of either dose. Repeat implants have been safe to date.
•· All patients show improved blood glucose control as reflected by a decrease in their glycated haemoglobin (%HbA1c) level after the implant, apart from Patient #6.
•· All blood glucose levels in the seven-point recordings at last follow-up were in the normal range for patients #1, #2, #3, #4, #7. The mean glucose level in all patients is within the range of 5.8 to 8.2 mMol/L. At last follow up, Patient #6 recorded a mean blood glucose of 9.4 mMol/L.
•· Two patients, #2 and #7, have both shown an excellent response and do not require exogenously administered insulin.
•- Patient #2 is a 37 year old female with a 15-year history of insulin dependent diabetes. This patient has received two implants of 5,000 IEQ/kg and in February 2009 a third implant of 10,000 IEQ/kg. Prior to the first implant this patient required an average daily insulin dose of 22 units/day. This patient's HbA1c level prior to implant was 8.2% and is currently 7.1%, her current mean blood glucose level is normal at 6.8 mMol/L.
•- Patient #7 is a 63 year old male with a 5-year history of insulin dependent diabetes. He received one implant at the dose of 10,000 IEQ/kg in January 2009. Prior to implant this patient required an average daily insulin dose of 37 units/day. This patient's HbA1c level prior to implant was 8.3% and is currently 4.8%, his current mean blood glucose level is normal at 6.6 mMol/L
•· As previously reported, capsules containing viable cells have been retrieved from second implants and porcine insulin has been detected in blood of patients following glucose tolerance test
•· The body weight of all patients during the study varied by less than 5% of their pre-implant weight.
Table: Preliminary Efficacy Response Data
|
Patient No. |
No. of Implants |
Follow-up (Weeks) |
Insulin Dose (Units/day) |
% Dose Reduction |
HbA1c (%) |
Current Mean Glucose (mMol/L) |
||
|
Pre-Implant |
Current |
Pre-Implant |
Current |
|||||
|
1 |
2 |
96 |
113 |
76 |
33 |
7.1 |
6.1 |
6.9 |
|
2 |
3 |
84 |
22 |
0 |
100 |
8.2 |
7.1 |
6.8 |
|
3 |
2 |
72 |
60 |
53 |
12 |
10.0 |
7.4 |
7.3 |
|
4 |
2 |
60 |
30 |
27 |
10 |
7.6 |
6.5 |
5.8 |
|
5 |
2 |
30 |
68 |
48 |
29 |
9.8 |
7.2 |
8.2 |
|
6* |
1 |
20* |
41 |
57* |
- |
8.5 |
8.5* |
9.4* |
|
7 |
1 |
18 |
37 |
0 |
100 |
8.3 |
4.8 |
6.6 |
* Patient lost to follow-up (data* at 20 weeks follow-up)
Summary: The Phase I/II dose escalation trial to date has implanted seven insulin dependent diabetes patients with one to three implants of DIABECELL® without remarkable adverse events. Preliminary efficacy data show normalised blood glucose levels and improved HbA1c with reduction of daily insulin dose. Two recipients have discontinued insulin injections.
Presentation by Professor Bob Elliott
Title: Practical, Methodological, Regulatory Aspects of Islet Cell Implants - DIABECELL®.
International Society for Cell Therapy 15th Annual Meeting
5th May 2009 at 1:30 -3:00 pm US Pacific Time
Sheraton, San Diego, CA, USA
Living Cell Technologies Welcomes Report On Safety of Pig Cell Transplants
08 April, 2009 - Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) says that the safety of using pig cells as a method of treatment has been supported by leading international virologists in an independent sci
COMPANY ANNOUNCEMENT
Living Cell Technologies Welcomes Report On Safety of Pig Cell Transplants
April 8, 2009 - Sydney, Australia and Auckland, New Zealand- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) says that the safety of using pig cells as a method of treatment has been supported by leading international virologists in an independent scientific paper. The report published recently in the science journal Xenotransplantation indicated that even large doses of pig retroviruses injected into monkeys did not cause infection or disease.
LCT's product comprising encapsulated insulin-producing pig cells, DIABECELL®, is in clinical trial for the treatment of type 1 diabetes without the use of immunosuppressive drugs.
LCT medical director, Professor Bob Elliott, said: "This report goes a long way to eliminating concerns that endogenous retroviruses from pig cells would infect people who receive pig cell transplants.
Large amounts of live viruses and viruses modified to infect human cells in culture were injected into monkeys and baboons without causing disease. The animals were given three different immunosuppressive drugs to weaken their immune system and exposure to significant amounts of these viruses still did not result in retroviral infection as no proviral DNA was found integrated in recipient cells or organs after 11 months.
DIABECELL® is given without immunosuppressive drugs so that our patients retain a healthy immune system. LCT's pigs do not secrete infectious virus and are tested regularly to be free of other viruses, bacteria and parasites."
Dr Paul Tan, LCT CEO, said: "The report is consistent with LCT's experience with providing pig cell implants for 18 patients under previous regulations. LCT reported no evidence of pig transmitted infections up to nine years following the implants.
The risk of pig retroviral infection has always been theoretical as it has never occurred. This new report shows that infection does not occur even in monkeys made susceptible to infection."
The paper published in the most recent issue of Xenotransplantation describes a study with rhesus monkeys, pig-tailed monkeys and baboons that were given the immunosuppressant drugs cyclosporine A, methylprednisolone and the rapamycin derivative to induce a state of chronic immunosuppression. Before inoculation with porcine endogenous retroviruses (PERV), complement activation was blocked with C1 esterase inhibitor. The authors concluded that "neither the inoculation of cell-free nor cell-associated PERV using a virus already adapted to primate cells results in an infection; this is despite the fact that peripheral blood mononuclear cells of the same animals are infectible in vitro."
References:
Specke V, Plesker R, Wood J, Coulibaly C, Suling K, Patience C, Kurth R, Schuurman HJ, Denner J. No in vivo infection of triple immunosuppressed non-human primates after inoculation with high titres of porcine endogenous retroviruses. Xenotransplantation 2009 Jan;16 (1): 34-44.
Garkavenko O, Croxson MC, Irgang M, Karlas A, Denner J and Elliott RB. Monitoring for presence of potential xenotic viruses in recipients of pig islet xenotransplantation. Journal of Clinical Microbiology 2004; 42: 5353- 5356
Click here to download this release in PDF format.
LCT quarterly newsletter
15 March, 2009 - March issue We start 2009 in a world that is changing dramatically. In this climate, LCT has to make sure that we have a business strategy that will take DIABECELL® to clinical and commercial success.
Click here to download this release in PDF format.Half yearly report
02 March, 2009 - Living Cell Technologies half yearly report for the period ended 31 December 2008
Sydney, Australia, Auckland, New Zealand - Living Cell Technologies (ASX:LCT; OTCQX:LVCLY) today announced the half yearly report for the six months ended 31 December 2008.
Click here to download this release in PDF format.Clinical Update
11 February, 2009 - Living Cell Technologies Reports Interim Results Showing Sustained Benefit With DIABECELL® Implants for Insulin Dependent Diabetes February 11, 2009 - Sydney, Australia, Auckland, New Zealand- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) reports positive interim results from the long term follow-up of insulin dependent diabetes patients in the Phase I/IIa clinical trial of its lead product, DIABECELL®.
Click here to download this release in PDF format.Quarterly report
30 January, 2009 - Quarterly cash flow report for the period ended 31 December 2008
Sydney, Australia, Auckland, New Zealand - Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the quarterly cash flow report for the quarter ended 31 December 2008. The appendix 4C is attached.
The cash balance at the end of the quarter was $7,235,292 compared to $8,670,253 at the end of the quarter to 30 September 2008.
Click here to download this release in PDF format.LCT conserves funds
23 December, 2008 - Living Cell Technologies Conserves Funds with Leaner Management December 23, 2008 - Sydney, Australia, Auckland, New Zealand - Living Cell Technologies (ASX: LCT, OTCQX: LVCLY) today announced that Dr Robert Caspari is standing down as Chief Executive Officer of the Company but remains on the Board of Directors.
Click here to download this release in PDF format.LCT announces collaboration with Centocor Research & Development
18 December, 2008 - Living Cell Technologies Announces collaboration with Centocor Research & Development, Inc.
December 18, 2008 - Sydney, Australia, Auckland, New Zealand and Boulder, Colorado, US - Living Cell Technologies Limited (ASX: LCT, OTCQX LVCLY) today announced that the Company has commenced a research agreement with Centocor Research & Development, Inc. (Centocor). Through this agreement, Centocor will have access to LCT's proprietary encapsulation technology.
Click here to download this release in PDF format.LCT`s NeurotrophinCell effective in Parkinson`s disease
12 November, 2008 - Preclinical Studies Suggest that Living Cell Technologies' NeurotrophinCell is Effective in Parkinson's Disease December 11, 2008 - Melbourne, Australia, Auckland, New Zealand and Boulder, USA - Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today reported that its pipeline product, NeurotrophinCell (NtCell), encapsulated brain choroid plexus cells, may be beneficial in Parkinson's disease.
Click here to download this release in PDF format.Living Cell Technologies reports on 12-month clinical effects of DiabeCell® at Annual General Meeting
06 November, 2008 - November 6, 2008 - Sydney, Australia, Auckland, New Zealand and Boulder, USA -
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today updated shareholders at their Annual General Meeting in Adelaide, Australia on the Phase I/IIa clinical trial of DiabeCell®, LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.
Click here to download this release in PDF format.Living Cell Technologies expands breeding capability with new production facility
23 October, 2008 - Melbourne, Australia, Auckland, New Zealand and Boulder, USA - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY) today announced that it will expand its breeding capabilities with the construction of a new Designated Pathogen Free Facility (DPF) facility for the breeding of LCT's unique pig herd.
Click here to download this release in PDF format.Living Cell Technologies Receives Health Minister's Approval to Start Leading Edge Live Cell Therapy Clinical Trial in New Zealand for Diabetics
21 October, 2008 - Living Cell Technologies today announced
that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell®, LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.
Click here to download this release in PDF format.NOTICE OF ANNUAL GENERAL MEETING
07 October, 2008 - Living Cell Technology gives notice of their Annual General Meeting to be held at to be held at 1.00 pm on Thursday 6 November 2008 at Stamford Plaza Hotel, Clare Room, 150 North Terrace, Adelaide SA
Click here to download this release in PDF format.Annual Report
07 October, 2008 - Living Cell Technology's 2008 Annual Report
Living Cell Technologies (LCT) is a global company focused on developing cell-based therapy products to treat life threatening human diseases. The Company has offices in Australia, New Zealand and the USA and is listed on the Australian Stock Exchange as well as the international OTCQX.
Click here to download this release in PDF format.Preliminary Final Report for the year ended 30 June, 2008
28 August, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY) today announced the Preliminary Final report (Appendix 4E) on the results for the year ended 30 June, 2008. In accordance with Listing Rule 4.3A, the report is linked below.
Click here to download this release in PDF format.Living Cell Technologies Announces Appendix 4C Quarterly Report
31 July, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY)
today announced that the cash balance at the end of the quarter was $10,767,335 compared to $12,689,973 at the end of the quarter to March 31st 2008.
Click here to download this release in PDF format.Living Cell Technologies Expands its Management Team and Appoints Dr Robert Caspari as CEO
29 July, 2008 - Melbourne, Australia; Auckland, New Zealand; and Boulder, Colorado,U.S.A. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced theexpansion of its management team and the appointment of one of its directors, Dr. RobertCaspari, M.D., as Chief Executive Officer of the Company.
Click here to download this release in PDF format.Living Cell Technologies Reports Clinical Benefit for All Patients in Diabetes Trial
22 July, 2008 - Melbourne, Australia and Auckland, New Zealand. Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY)
today released further interim results describing clinical benefit in all patients who have received implants of DiabeCell®, the Company’s encapsulated porcine islet cells for the treatment of type 1 diabetes.
Click here to download this release in PDF format.Living Cell Technologies Hosts Diabetes Seminar for World Leaders in Porcine Islet Implants in Humans
17 July, 2008 - Melbourne, Australia and Auckland, New Zealand. Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that Professor Bob Elliott, Medical Director of LCT, will host a seminar on Friday August 8, 2008 in Auckland, New Zealand for world leading medical scientists and specialists to discuss current developments with porcine islet transplant technologies.
Click here to download this release in PDF format.LCT Quarterly Newsletter
01 July, 2008 -
Living Cell Technologies present the July issue of the quarterly investor newsletter.
Click here to download this release in PDF format.LCT Expands Diabetes Clinical Trial
08 June, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) today announced that the positive preliminary data from its first clinical trial of Diabecell® for insulin dependent type 1 diabetes has encouraged the Company to expand the trial and proceed with testing higher doses.
Click here to download this release in PDF format.LCT lists on the International OTCQX
03 June, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY)
today announced that it has listed its American Depositary Receipts (“ADRs”) on the International OTCQX and began trading Monday, June 2nd in the United States.
Click here to download this release in PDF format.Channel Ten feature LCT technology
08 May, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY) today announced that Australian television Channel Ten News will feature the Company’s world first islet cell treatment being developed for insulin dependent diabetes on its news segment between 5.00pm - 6.00pm this evening.
Click here to download this release in PDF format.OTCQX listing planned to further open exposure to US investors
08 May, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY)
today announced it has applied to list its American Depository Receipt (ADR) program on the International OTCQX to increase the Company’s exposure to U.S. investors.
Click here to download this release in PDF format.Encapsulation technology presented to international conference in Florida
05 May, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) today announced that the Company has been invited to deliver a presentation on its unique encapsulation technology at the International Particles 2008 conference being held in Orlando, Florida, USA from May 10th -12th.
Click here to download this release in PDF format.LCT showcases proprietary nanotech
02 April, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY)
today announced that Dr. Paul Tan, LCT CEO and Dr. Anil K Anal, LCT Material Scientist, presented data at a session on nanotechnology at the NZBio 2008 Conference in Auckland, New Zealand.
Click here to download this release in PDF format.LCT announces Positive 6 month trial interim results
31 March, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) today announced new positive 6 month interim results from the Phase I/IIa clinical trial of DiabeCell® for the treatment of type 1 diabetes at the International Diabetes Federation (IDF) Congress in Wellington, New Zealand and the NZBio Conference in Auckland, New Zealand.
Click here to download this release in PDF format.Living Cell Technologies and US- Based Barbara Davis Center to collaborate on Diabetes Clinical Trial Program
27 February, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK)
today announced that the Company has signed a term sheet with the Barbara Davis Center for Childhood Diabetes (BDC) to establish a diabetes clinical trial program in Denver, Colorado.
Click here to download this release in PDF format.Living Cell Technologies to Present Positive Preliminary Clinical Results at the International Diabetes Federation Congress
13 February, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that the Company's positive preliminary clinical results will be presented at the upcoming 7th International Diabetes Federation (IDF) Western Pacific Region Congress.
Click here to download this release in PDF format.Diabetes Trial Supported By US-Based Diabetes Foundation
12 February, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK)
today announced that the US based Children with Diabetes Foundation (CWDF), has offered its support in raising funds for LCT’s DiabeCell® clinical trials for people with type 1 diabetes. The foundation has established a fund which allows supporters of diabetes research to contribute tax deductible donations towards the trials.
Click here to download this release in PDF format.Living Cell Technologies Announces Conversion by Noteholders
25 January, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that its convertible noteholders have agreed to convert all the convertible notes issued by LCT on June 29, 2006, into ordinary shares of LCT.
Click here to download this release in PDF format.Living Cell Technologies to Receive US$6.0M through Exercise of Option
09 January, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK)
today announced that Palmert Members Limited (a British Virgin Island company) will purchase 24,150,408 ordinary shares of LCT at A$0.29 per share for an aggregate purchase price of US$6.0 million. Palmert will make this investment through exercising an option that was granted to NaviGroup Management Limited and assigned to Palmert by NaviGroup. The option, which expires on January 24, 2008 was exercised on December 20, 2007 and allows the holder to purchase up to US$6.0 million of LCT’s ordinary shares at 80% of the 30-day average closing bid price per ordinary share of the Company. The issue of these shares will occur at an exchange rate of US$0.8567 per AU$1.00 and is subject to certain shareholder approvals.
Click here to download this release in PDF format.Living Cell Technologies Appoints New US-Based Director
08 January, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced the appointment of Dr. Robert Caspari of Boulder, Colorado to LCT’s Board of Directors as a Non Executive Director.
Click here to download this release in PDF format.Living Cell Technologies Has the Funds to Capatilise on the Opportunities of 2008 - Australian Investor Article
01 January, 2008 - The Australian Investor
2007 was an exciting year for Living Cell Technologies, with the commencement of its clinical trials for its diabetes product in Russia. The preliminary results of this trial have been very encouraging and should provide a solid foundation for the Company moving forward in 2008.
Click here to download this release in PDF format.Search our site
DIABECELL®
Natural neo-natal porcine islets encapsulated in an alginate gel and transplanted for the treatment of insulin-dependent diabetes.
More InformationNTCell
A choroid plexus cell product with the potential to treat neurological diseases such as Parkinson’s disease and stroke.
More InformationFac8Cell
A liver cell product aimed at producing factor 8, a blood clotting agent absent or defective in people suffering haemophilia.
More InformationEncapsulation Technology
LCT’s technology platform involves the implantation of healthy living cells to replace, repair or regenerate diseased or damaged organs.
More InformationVideos
The Advances in Porcine Islet Implants for the Treatment of Type 1 Diabetes Symposium.
More Information